... Food and Drug Administration Highlights of Prescribing Information: Elrexfio — Pfizer Highlights of Prescribing Information: Lynozyfic — Regeneron Pharmaceuticals Highlights of Prescribing Information: Talvey — Janssen Pharmaceutical Companies What Do Clinical Trial Results Mean? ...
... Healthcare Database (SNDS) — Annals of Hematology The Value of Survival Gains From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... Healthcare Database (SNDS) — Annals of Hematology The Value of Survival Gains From Therapeutic Innovations for US Patients With Relapsed/Refractory Multiple Myeloma — Therapeutic Advances in Hematology Multiple Myeloma With High-Risk Cytogenetics and Its Treatment Approach — International Journal of Hematology FDA DISCO Burst Edition: FDA Approvals of Talvey ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... (CAR) T-cell therapy, which modifies a person’s T cells to better target myeloma cells Teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, which helps T cells find and destroy myeloma cells Elranatamab-bcmm (Elrexfio), a BCMA-directed CD3 T-cell engager approved in 2023 Talquetamab-tgvs (Talvey ...
Relapsed vs. Refractory Myeloma: 5 Facts To Know
... (CAR) T-cell therapy, which modifies a person’s T cells to better target myeloma cells Teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, which helps T cells find and destroy myeloma cells Elranatamab-bcmm (Elrexfio), a BCMA-directed CD3 T-cell engager approved in 2023 Talquetamab-tgvs (Talvey ...
... Since then, the FDA has approved three new BiTES: elranatamab-bccm (Elrexfio), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic).Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey ...
Multiple Myeloma – An Overview
... individuals with relapsed or refractory multiple myeloma.In 2019, the FDA approved selinexor (Xpovio), offering a new mechanism of action as a selective inhibitor of nuclear export.The approval of isatuximab-irfc (Sarclisa) in 2020, along with newer bispecific T-cell engagers like teclistamab-cqyv (Tecvayli, approved in 2022), as well as talquetamab-tgvs (Talvey ...
... Talquetamab (Talvey) is a bispecific T-cell engager approved in 2023 for people with RRMM who have tried four lines of therapy. In 2025, the FDA approved linvoseltamab-gcpt (Lynozyfic) for adults with RRMM who have received four or more prior lines of treatment.BiTEs work by targeting BCMA and the CD3 protein found in T cells. ...
Myeloma Relapse Rates and 9 Treatment Options for Relapses
... Talquetamab (Talvey) is a bispecific T-cell engager approved in 2023 for people with RRMM who have tried four lines of therapy. In 2025, the FDA approved linvoseltamab-gcpt (Lynozyfic) for adults with RRMM who have received four or more prior lines of treatment.BiTEs work by targeting BCMA and the CD3 protein found in T cells. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
12 Myeloma Treatment Options
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
Join